Oyarzabal Santamarina
Julen Oyarzabal Santamarina, Madrid ES
Patent application number | Description | Published |
---|---|---|
20110046127 | Imidazopyridazines for Use as Protein Kinase Inhibitors - There is provided compounds of formula (I): wherein Z, M, R | 02-24-2011 |
20120083492 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS - There is provided compounds of formula (I), wherein R | 04-05-2012 |
20130065883 | Triazolo [4, 5- B] Pyridin Derivatives - There is provided compounds of formula (I), wherein R | 03-14-2013 |
20140154232 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing - The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual. | 06-05-2014 |
20140315903 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors - The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) | 10-23-2014 |
Julen Oyarzabal Santamarina, Toledo SE
Patent application number | Description | Published |
---|---|---|
20100166655 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS - The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) | 07-01-2010 |
Julen Oyarzabal Santamarina, Olias Del Rey ES
Patent application number | Description | Published |
---|---|---|
20100105694 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE - The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in claim | 04-29-2010 |
Julen Oyarzabal Santamarina, Olias Del Rey (toledo) ES
Patent application number | Description | Published |
---|---|---|
20090012062 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases - The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity according to the general Formula (I) | 01-08-2009 |
20090111801 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE - The present invention concerns substituted pyrazinone derivatives according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim | 04-30-2009 |
20090281099 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE - The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) | 11-12-2009 |
Julen Oyarzabal Santamarina, Pamplona ES
Patent application number | Description | Published |
---|---|---|
20150175618 | NEW ANTIFIBRINOLYTIC COMPOUNDS - It relates to spirocyclic compounds of formula (I), or pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds of formula (I) or of their pharmaceutically or veterinary acceptable salts, wherein A and B form a spirocyclic ring system wherein the spiro atom connecting A and B is a carbon atom and wherein A is a known 3- to 8-membered carbocyclic or heterocyclic monocyclic ring or a known 6- to 18-membered carbocyclic or heterocyclic polycyclic ring system; B is a known 4- to 7-membered carbocyclic or heterocyclic monocyclic ring; C is phenyl or a known 5- to 6-membered heteroaromatic ring; and R | 06-25-2015 |